Scores here are heuristic signals about sourcing and corroboration across outlets — not verdicts on whether a story is true, and not an endorsement or condemnation of any outlet. How this works
A year after their first antibody-drug conjugate (ADC) team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion b | A year after their first antibody-drug conjugate team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 b…
1
independent outlets · 100% owner-diverse
Save this story
Connect "Roche returns to China’s Hansoh for $15B biobucks ADC pact - Fierce Biotech" to your own research notes and market positions — Next Level Intelligence links what you save to the assets and notes it actually affects.